Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association (2010) CA Cancer J Clin 60: 194-201 Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) N Engl J Med 363: 411-22 Inhibition of nuclear hormone receptor activity by calreticulin. Dedhar S, Rennie PS, Shago M, Hagesteijn CY, Yang H, Filmus J, Hawley RG, Bruchovsky N, Cheng H, Matusik RJ (1994) Nature 367: 480-3 Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA (2010) J Clin Oncol 28: 1069-74 Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS (2016) J Clin Oncol 34: 2098-106 Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association (2010) Circulation 121: 833-40 Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer AM, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, Roden DM, Bachelot A, Funck-Brentano C (2018) Circulation 138: 110-113 Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J (2016) Circulation 133: 537-41 Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J (2015) Circulation 132: e218-20 Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Nat Rev Clin Oncol 13: 674-690 Urological cancer: walking the tightrope of survival and quality of life with ADT. Resnick MJ (2013) Nat Rev Clin Oncol 10: 307-8 Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. Andriani F, Nan B, Yu J, Li X, Weigel NL, McPhaul MJ, Kasper S, Kagawa S, Fang B, Matusik RJ, Denner L, Marcelli M (2001) J Natl Cancer Inst 93: 1314-24 TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, Translational Breast Cancer Research Consortium (2020) Clin Cancer Res 26: 2111-2123 Molecular alterations in primary prostate cancer after androgen ablation therapy. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF (2005) Clin Cancer Res 11: 6823-34 Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ (2015) Oncogene 34: 3700-10 Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R (2016) Oncotarget 7: 61955-61969 Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses. Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ (2020) Arterioscler Thromb Vasc Biol 40: e55-e64 Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Ricke EA, Williams K, Lee YF, Couto S, Wang Y, Hayward SW, Cunha GR, Ricke WA (2012) Carcinogenesis 33: 1391-8 Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D (2020) Eur J Heart Fail 22: 1945-1960 Prostate cancer: quality of life after radiation and androgen deprivation. Makarov DV, Penson DF (2009) Nat Rev Urol 6: 477-8 Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD (2001) Mol Endocrinol 15: 46-56 Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Zeliadt SB, Potosky AL, Penson DF, Etzioni R (2006) Int J Radiat Oncol Biol Phys 66: 395-402 Androgen receptor-mediated repression of novel target genes. Prescott J, Jariwala U, Jia L, Cogan JP, Barski A, Pregizer S, Shen HC, Arasheben A, Neilson JJ, Frenkel B, Coetzee GA (2007) Prostate 67: 1371-83 Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL (2012) PLoS One 7: e34414 Castration-resistant prostate cancer: AUA Guideline. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS (2013) J Urol 190: 429-38 The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M (2005) J Urol 174: 547-52; discussion 552 Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM (2007) J Urol 177: 1307-12 Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O (2021) Urol Oncol 39: 52-62 A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. Blobaum AL, Byers FW, Bridges TM, Locuson CW, Conn PJ, Lindsley CW, Daniels JS (2015) Drug Metab Dispos 43: 1718-26 Capsule commentary on Shahinian et al.: Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer. Penson DF (2013) J Gen Intern Med 28: 1494 Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, Penson DF (2013) BJU Int 111: 213-20 Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL (2015) BJU Int 116: 358-65 Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE (2012) BJU Int 110: E721-6 Inhibition of androgen action by dehydroepiandrosterone sulfotransferase transfected in PC-3 prostate cancer cells. Chan J, Song CS, Matusik RJ, Chatterjee B, Roy AK (1998) Chem Biol Interact 109: 267-78 Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Lloyd A, Penson D, Dewilde S, Kleinman L (2008) Prostate Cancer Prostatic Dis 11: 153-9 Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF (2013) Urology 82: 410-5 Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D (2005) Urology 66: 835-9 Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Tsai HT, Penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL (2013) Urology 82: 327-33 Quality of life with advanced metastatic prostate cancer. Resnick MJ, Penson DF (2012) Urol Clin North Am 39: 505-15
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.